Last updated 2026-06-18
- Raised funding round led by Israel Biotech Fund, Jul 2021
Total raised
—
Last: 2021-07
Stage
Seed
Founded
2021
Headcount
6
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
Peles Therapeutics is developing a humanized monoclonal antibody targeting the receptor for advanced glycation end products. With technology in-licensed from Columbia University, the company aims to address the unmet need of peripheral artery disease in diabetic patients using this novel approach.
Funding history · 1 round · — total
2021-07
Undisclosed
Q&A
- What is the primary focus of Peles Therapeutics?
- Peles Therapeutics is developing a humanized monoclonal antibody treatment for peripheral artery disease, specifically targeting the receptor for advanced glycation end products.
- When was Peles Therapeutics founded?
- Peles Therapeutics was founded in May 2021.
- What is the current status of Peles Therapeutics?
- Peles Therapeutics is currently inactive, having ceased operations in August 2022.
- From where did Peles Therapeutics license its core technology?
- Peles Therapeutics in-licensed its technology from Columbia University.
- How many employees did Peles Therapeutics have?
- Peles Therapeutics had 1-10 employees.
- Which investor participated in Peles Therapeutics' funding round?
- Israel Biotech Fund participated in Peles Therapeutics' funding round in July 2021.
- What is the primary sector of Peles Therapeutics?
- Peles Therapeutics operates in the Health Tech & Life Sciences sector.
- What is the product stage of Peles Therapeutics' development?
- Peles Therapeutics' product is in the R&D stage.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
patientstherapeuticsdiabetesdrug-developmentantibodies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2021-5 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, Aug 2022 ceased to operate |